用SCH39304治疗实验性隐球菌性脑膜炎和播散性念珠菌病。
Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.
作者信息
Perfect J R, Wright K A, Hobbs M M, Durack D T
机构信息
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
出版信息
Antimicrob Agents Chemother. 1989 Oct;33(10):1735-40. doi: 10.1128/AAC.33.10.1735.
Abstract
We studied the pharmacokinetics and in vivo antifungal action of SCH39304, a new antifungal azole compound, in rabbits. It crossed the blood-cerebrospinal fluid barrier in the presence or absence of meningeal inflammation, reaching approximately 60% of the simultaneous concentrations in serum. In the treatment of experimental cryptococcal meningitis, SCH39304 was as effective as fluconazole in reducing yeast counts in the subarachnoid space. SCH39304 and fluconazole both were highly effective against candida endophthalmitis, sterilizing the vitreous humor and the choroid and retina. SCH39304 suppressed candida endocarditis and reduced yeast counts in the kidney at all doses tested. SCH39304 was effective in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. Further investigations in humans are warranted.
摘要
我们在兔体内研究了新型抗真菌唑类化合物SCH39304的药代动力学及体内抗真菌作用。无论有无脑膜炎症，它均可穿过血脑屏障，其浓度约为同时期血清浓度的60%。在治疗实验性隐球菌性脑膜炎时，SCH39304在降低蛛网膜下腔酵母菌数量方面与氟康唑效果相当。SCH39304和氟康唑对念珠菌性眼内炎均有高效，可使玻璃体液、脉络膜和视网膜除菌。在所有测试剂量下，SCH39304均可抑制念珠菌性心内膜炎并减少肾脏中的酵母菌数量。SCH39304对实验性隐球菌性脑膜炎和播散性念珠菌病的治疗有效。有必要在人体中进行进一步研究。
相似文献
1
Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.用SCH39304治疗实验性隐球菌性脑膜炎和播散性念珠菌病。
Antimicrob Agents Chemother. 1989 Oct;33(10):1735-40. doi: 10.1128/AAC.33.10.1735.
2
Efficacy of SCH39304 in murine cryptococcosis.SCH39304对小鼠隐球菌病的疗效。
Antimicrob Agents Chemother. 1989 Aug;33(8):1242-6. doi: 10.1128/AAC.33.8.1242.
3
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.伊曲康唑与氟康唑治疗兔隐球菌性脑膜炎和念珠菌性肾盂肾炎的比较。
Antimicrob Agents Chemother. 1986 Apr;29(4):579-83. doi: 10.1128/AAC.29.4.579.
4
The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis.BAY R3783的药代动力学及其在治疗实验性隐球菌性脑膜炎中的疗效。
J Antimicrob Chemother. 1990 Sep;26(3):387-97. doi: 10.1093/jac/26.3.387.
5
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.唑类药物SCH56592对新型隐球菌的体外和体内疗效。
Antimicrob Agents Chemother. 1996 Aug;40(8):1910-3. doi: 10.1128/AAC.40.8.1910.
6
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.新型口服三唑类抗真菌药ER-30346在曲霉病、念珠菌病和隐球菌病实验模型中的疗效。
Antimicrob Agents Chemother. 1996 Oct;40(10):2243-7. doi: 10.1128/AAC.40.10.2243.
7
Discovery of New Tricyclic Oxime Sampangine Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcosis and Candidiasis.发现新型三环肟沙蓬碱衍生物，作为治疗隐球菌病和念珠菌病的强效抗真菌药物。
J Med Chem. 2024 Mar 28;67(6):4726-4738. doi: 10.1021/acs.jmedchem.3c02331. Epub 2024 Mar 15.
8
Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit.氟康唑对兔实验性隐球菌病和念珠菌病的治疗作用
Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S299-302. doi: 10.1093/clinids/12.supplement_3.s299.
9
Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.高剂量氟康唑联合两性霉素B与高剂量氟康唑联合5-氟胞嘧啶对比两性霉素B、氟康唑及5-氟胞嘧啶单药疗法治疗白色念珠菌所致实验性心内膜炎、眼内炎和肾盂肾炎的疗效
Antimicrob Agents Chemother. 1999 Dec;43(12):2831-40. doi: 10.1128/AAC.43.12.2831.
10
In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.新型芳脒T-2307的体外和体内抗真菌活性
Antimicrob Agents Chemother. 2008 Apr;52(4):1318-24. doi: 10.1128/AAC.01159-07. Epub 2008 Jan 28.
引用本文的文献
1
The Rabbit Model of Cryptococcal Meningitis.隐球菌性脑膜炎兔模型。
Methods Mol Biol. 2024;2775:13-27. doi: 10.1007/978-1-0716-3722-7_2.
2
Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis.APX2039 在兔隐球菌性脑膜炎模型中的疗效。
mBio. 2022 Dec 20;13(6):e0234722. doi: 10.1128/mbio.02347-22. Epub 2022 Oct 12.
3
Pathogenesis of pulmonary Cryptococcus gattii infection: a rat model.肺组织隐球菌病的发病机制：大鼠模型。
Mycopathologia. 2010 Nov;170(5):315-30. doi: 10.1007/s11046-010-9328-z. Epub 2010 Jun 15.
4
In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.新型三唑类药物阿巴康唑对新型隐球菌的体内外疗效
Antimicrob Agents Chemother. 2004 Feb;48(2):384-7. doi: 10.1128/AAC.48.2.384-387.2004.
5
In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans.三唑类药物TAK-187对新型隐球菌的体外和体内疗效
Antimicrob Agents Chemother. 1998 Oct;42(10):2630-2. doi: 10.1128/AAC.42.10.2630.
6
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.唑类药物SCH56592对新型隐球菌的体外和体内疗效。
Antimicrob Agents Chemother. 1996 Aug;40(8):1910-3. doi: 10.1128/AAC.40.8.1910.
7
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.艾滋病时代的隐球菌病——新型隐球菌发现100年后
Clin Microbiol Rev. 1995 Oct;8(4):515-48. doi: 10.1128/CMR.8.4.515.
8
The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.编码磷酸核糖氨基咪唑羧化酶（ADE2）的基因对于新型隐球菌在脑脊液中的生长至关重要。
Infect Immun. 1993 Oct;61(10):4446-51. doi: 10.1128/iai.61.10.4446-4451.1993.
9
Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.三唑类抗真菌药吉纳康唑在健康男性口服和静脉给药后的药代动力学
Antimicrob Agents Chemother. 1994 Dec;38(12):2758-62. doi: 10.1128/AAC.38.12.2758.
10
Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent.新型三唑类抗真菌剂SCH 39304治疗小鼠肺芽生菌病
Antimicrob Agents Chemother. 1990 May;34(5):896-8. doi: 10.1128/AAC.34.5.896.
本文引用的文献
1
Chronic cryptococcal meningitis: a new experimental model in rabbits.慢性隐球菌性脑膜炎：家兔新实验模型
Am J Pathol. 1980 Oct;101(1):177-94.
2
Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis.酮康唑治疗进行性球孢子菌病三种主要表现形式的经验。
Am J Med. 1983 Jan 24;74(1B):58-63. doi: 10.1016/0002-9343(83)90515-6.
3
Treatment of paracoccidioidomycosis with ketoconazole: a three-year experience.酮康唑治疗副球孢子菌病：三年经验
Am J Med. 1983 Jan 24;74(1B):48-52. doi: 10.1016/0002-9343(83)90513-2.
4
Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients.酮康唑治疗慢性黏膜皮肤念珠菌病的长期疗效：21例患者的经验
Am J Med. 1983 Jan 24;74(1B):23-9. doi: 10.1016/0002-9343(83)90511-9.
5
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.酮康唑治疗系统性真菌病：52例患者的毒性及临床反应重点。美国国立过敏和传染病研究所抗真菌协作研究。
Ann Intern Med. 1983 Jan;98(1):13-20. doi: 10.7326/0003-4819-98-1-13.
6
Oral ketoconazole. An effective and safe treatment for dermatophytosis.
Arch Dermatol. 1981 Mar;117(3):129-34. doi: 10.1001/archderm.117.3.129.
7
Obfuscation of the activity of antifungal antimicrobics by culture media.培养基对抗真菌抗菌剂活性的干扰。
J Infect Dis. 1972 Oct;126(4):353-61. doi: 10.1093/infdis/126.4.353.
8
Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis.两性霉素B与N-D-鸟氨酰两性霉素B甲酯在实验性新型隐球菌脑膜炎及白色念珠菌性肾盂肾炎合并心内膜炎中的比较。
Antimicrob Agents Chemother. 1985 Dec;28(6):751-5. doi: 10.1128/AAC.28.6.751.
9
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.伊曲康唑与氟康唑治疗兔隐球菌性脑膜炎和念珠菌性肾盂肾炎的比较。
Antimicrob Agents Chemother. 1986 Apr;29(4):579-83. doi: 10.1128/AAC.29.4.579.
10
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits.咪唑类和三唑类药物在兔脑脊液中的渗透情况。
J Antimicrob Chemother. 1985 Jul;16(1):81-6. doi: 10.1093/jac/16.1.81.
Zotero 插件